



TO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO:	SERIAL NO..
	P-IX 2965	09/016,061
APPLICANT: William D. Huse		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 30, 1998	GROUP: 1644

U. S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
M		US 6,180,370 B1	1/30/01	Queen et al.	435	69.6	6/7/95

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

M	BIOTECHNOLOGY NEWSWATCH, pp. 11-12, 1/16/95
n	BIOTECHNOLOGY NEWSWATCH, pp. 11, 2/6/95
N	Studnicka et al., "Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Engineering</u> 7:805-814 (1994)

EXAMINER <i>P. Hump Granger</i>	DATE CONSIDERED <i>6/14/02</i>
------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.